Tamoxifen treatment and new-onset depression in breast cancer patients

Psychosomatics

Volumn 48, Issue 3, 2007, Pages 205-210

  Lee, Kelly C ^a   Ray, G Thomas ^b   Hunkeler, Enid M ^b   Finley, Patrick R ^b  

^a LOMA LINDA UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; FEMALE; HAZARD RATIO; HUMAN; POST HOC ANALYSIS; RETROSPECTIVE STUDY; RISK FACTOR;

EID: 34248677589     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.48.3.205     Document Type: Article

References (26)

1. Howe HL, Wu X, Ries LA, et al: Annual Report to the Nation on the Status of Cancer, 1975-2003, Featuring Cancer Among U.S. Hispanic/Latino Populations. North American Association of Central Cancer Registries, Springfield, IL, (62704-6495); hhowe@naaccr.org
2. Feting D: Depression in patients with breast cancer: prevalence, diagnosis, and treatment. Breast J 1997; 3:292-302
3. McDaniel J, Musselman D, Porter M: Depression in patients with cancer: diagnosis, biology, and treatment. Arch Gen Psychiatry 1995; 52:89-99
4. Moyer A, Salovery P: Psychosocial sequelae of breast cancer and its treatment. Behav Med 1996; 16:110-125
5. Thompson D, Spanier C, Vogel V: The relationship between tamoxifen, estrogen, and depressive symptoms. Breast J 1999; 5:375-382
6. Bober SL, Hoke LA, Duda RB, et al: Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol 2004; 22:4951-497
7. Lien EA, Wester K, Lonning PE, et al: Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br J Cancer 1991; 63:641-645
8. AstraZeneca Pharmaceuticals LP Nolvadex®: Tamoxifen Product Information. Wilmington, DE, 2005
9. Patten SB, Barbui C: Drug-induced depression: a systematic review to inform clinical practice. Psychother Psychosom 2004; 73:207-215
10. Duffy L, Greenberg D, Younger J, et al: Iatrogenic acute estrogen deficiency and psychiatric syndromes in breast cancer patients. Psychosomatics 1999; 40:304-308
11. Cathcart CK, Jones SE, Pumroy CS, et al: Clinical recognition and management of depression in node-negative breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 1993; 27:277-281
12. Fallowfield L, Fleissig A, Edwards R, et al: Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized, controlled trials. J Clin Oncol 2001; 19:1885-1892
13. Oehrli MD, Quesenberry CP, Leyden W, Northern California Cancer Registry, 2005: Annual Report on Trends, Incidence, and Outcomes. Kaiser Permanente Northern California Cancer Registry, Nov. 2005
14. Selby JV: Linking automated databases for research in managed-care settings. Ann Intern Med 1997; 127:719-724
15. Anelli TF, Anelli A, Tran KN, et al: Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer 1994; 74:74-77
16. Shariff S, Cumming C, Lees A: Mood disorder in women with early breast cancer taking tamoxifen, an estradiol receptor-antagonist: an expected or unexpected effect? Ann N Y Acad Sci 1995; 761:365-368
17. Breuer B, Anderson R: The relationship of tamoxifen with dementia, depression, and dependence in activities of daily living in elderly nursing home residence. Women Health 2000; 31:71-85
18. Day R, Ganz PA, Constantino JP: Tamoxifen and depression: more evidence from The National Surgical Adjuvant Breast and Bowel Project's breast cancer prevention (P-1) randomized study. J Natl Cancer Inst 2001; 93:1615-1623
19. Love RR, Cameron L, Connell BL, et al: Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 1991; 151:1842-1847
20. Hughson AV, Cooper AF, McArdle CS, et al: Psychological impact of adjuvant chemotherapy in the first two years after mastectomy. BMJ 1986; 293:1268-1271
21. van Dam FS, Schagen SB, Muller MJ, et al: Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998; 90:210-218
22. Nystedt M, Berglund G, Bolund C, et al: Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective, randomized study. J Clin Oncol 2003; 21:1836-1844
23. Razavi D, Farvacques C, Delvaux N, et al: Psychosocial correlates of oestrogen and progesterone receptors in breast cancer. Lancet 1990; 335:931-933
24. Rosenqvist S, Berglund G, Bolund C, et al: Lack of correlation between anxiety parameters and oestrogen-receptor status in early breast cancer. Eur J Cancer 1993; 29A:1325-1326
25. Bernoux A, de Cremoux P, Laine-Bidron C, et al: Estrogen-receptor negative and progesterone-receptor positive primary breast cancer: pathological characteristics and clinical outcome: Institut Curie Breast Cancer Study Group. Breast Cancer Res Treat 1998; 49:219-225
26. Bebbington PE, Dunn G, Jenkins R, et al: The influence of age and sex on the prevalence of depressive conditions: report from the National Survey of Psychiatric Morbidity. Psychol Med 1998; 28:9-19